Nuvectis Pharma reported cash from operations of -$4.53M and free cash flow of -$4.53M for the quarter ended Jun 2026, down 34.6% year over year. This cash flow statement covers 21 quarters of results from Jun 2021 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||||||||
| Net Income | -4.67M | -2.27M | -2.94M | -3.57M | -5.88M | -6.70M | -4.05M | -5.71M | -5.88M | -6.62M | -4.17M | -4.43M | -4.15M | -6.25M | -5.33M | -6.33M | -7.46M | -7.31M | -6.05M | -7.02M | |
| Share-based Compensation | 0.90M | 0.18M | 0.23M | 0.33M | 0.35M | 0.48M | 1.40M | 0.95M | 0.95M | 1.22M | 1.30M | 1.39M | 1.40M | 1.14M | 2.11M | 2.20M | 4.90M | 1.48M | 2.88M | 2.88M | |
| Cash from Operations | -4.43M | -1.07M | -3.08M | -2.54M | -4.42M | -3.52M | -4.78M | -4.08M | -3.24M | -3.85M | -4.36M | -3.02M | -2.40M | -2.46M | -4.17M | -3.37M | -4.49M | -3.97M | -6.51M | -4.53M | |
| Change in Working Capital | |||||||||||||||||||||
| Change in Account Payables | -0.81M | -0.29M | 1.69M | -0.72M | -1.01M | 0.09M | 0.41M | 0.24M | 0.49M | 1.99M | 1.46M | -0.17M | -1.58M | 0.49M | |||||||
| Change in Accured Expenses | 0.11M | 1.10M | 0.54M | 0.26M | 1.45M | -0.30M | -0.70M | 0.15M | 0.09M | 1.87M | -0.35M | 0.17M | 0.05M | 1.89M | -0.52M | -0.32M | 0.06M | 2.13M | -0.46M | 0.18M | |
| Financing Activities | |||||||||||||||||||||
| Other financing activities | 0.14M | 16.00M | 0.51M | 0.56M | 0.70M | 10.48M | 0.01M | ||||||||||||||
| Change in Capital Stock | |||||||||||||||||||||
| Net Shares Issued and Repurchased | 0.03M | 0.31M | 0.59M | 0.66M | 0.43M | 0.02M | |||||||||||||||
| Net Equity Issued and Repurchased | 4.02M | 1.13M | 0.90M | 4.85M | 1.70M | 1.50M | 3.95M | 15.53M | 0.60M | 13.50M | 0.17M | 0.01M | 0.20M | ||||||||
| Misc. | |||||||||||||||||||||
| Cash from Financing Activities | 4.02M | 14.03M | -0.58M | 14.49M | -0.13M | 0.25M | 13.21M | 0.70M | 0.92M | 4.70M | 1.67M | 1.46M | 3.83M | 15.51M | 0.30M | 13.14M | 0.17M | 0.01M | 1.56M | ||
| Change in Cash | -0.41M | -1.07M | 10.95M | -3.12M | 10.07M | -3.65M | -4.53M | 9.13M | -2.54M | -2.93M | 0.34M | -1.35M | -0.95M | 1.36M | 11.33M | -3.07M | 8.65M | -3.81M | -6.50M | -2.97M | |
| Free Cash Flow | -4.43M | -1.07M | -3.08M | -2.54M | -4.42M | -3.52M | -4.78M | -4.08M | -3.24M | -3.85M | -4.36M | -3.02M | -2.40M | -2.46M | -4.17M | -3.37M | -4.49M | -3.97M | -6.51M | -4.53M | |
| Net Cash Flow | -0.41M | -1.07M | 10.95M | -3.12M | 10.07M | -3.65M | -4.53M | 9.13M | -2.54M | -2.93M | 0.34M | -1.35M | -0.95M | 1.36M | 11.33M | -3.07M | 8.65M | -3.81M | -6.50M | -2.97M |